SueWallSt opens probe into Elicio Therapeutics officers, directors after 72.53% stock plunge

Elicio Therapeutics, Inc

Elicio Therapeutics, Inc

ELTX

0.00
  • SueWallSt opened a securities investigation into Elicio Therapeutics tied to disclosures on its ELI-002 7P pancreatic cancer program.
  • Shares fell 72.53% in one session following release of Phase 2 AMPLIFY-7P results that missed the primary disease-free survival endpoint.
  • The probe focuses on whether prior statements on ELI-002 7P prospects or the AMPLIFY-7P program were materially misleading.
  • The alert cited a June 9 Q1 2026 filing showing zero revenue and a widening net loss driven by higher R&D spending.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606161644PR_NEWS_USPR_____NY85224) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.